Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Photoimmunotherapy may be promising treatment option to combat cancer

Photoimmunotherapy may be promising treatment option to combat cancer

Compugen program shows potential for development of new immunotherapy treatments for solid tumors

Compugen program shows potential for development of new immunotherapy treatments for solid tumors

Broadly neutralizing antibody delays return of viral rebound in HIV-1 infected individuals

Broadly neutralizing antibody delays return of viral rebound in HIV-1 infected individuals

New biologic medication shows promise in treating multi-drug resistant HIV patients

New biologic medication shows promise in treating multi-drug resistant HIV patients

Anti-inflammatory drugs may improve severity of depressive symptoms, study finds

Anti-inflammatory drugs may improve severity of depressive symptoms, study finds

How could emerging technologies impact cancer care?

How could emerging technologies impact cancer care?

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Mayo Clinic article provides better understanding on potentially devastating liver disease

Mayo Clinic article provides better understanding on potentially devastating liver disease

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Added benefit not proven for new combination therapy in multiple myeloma

Added benefit not proven for new combination therapy in multiple myeloma

Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

LJI researchers reveal unanticipated way by which neutrophils defend against invading pathogens

LJI researchers reveal unanticipated way by which neutrophils defend against invading pathogens

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Added benefit not proven for orphan drug in treatment of adults with stomach cancer

Added benefit not proven for orphan drug in treatment of adults with stomach cancer

New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

Immunotherapy innovations in oncology: an interview with Robert LaCaze

Immunotherapy innovations in oncology: an interview with Robert LaCaze

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.